Loaiza Olman Rodríguez, Morales Sigrid, Norheim Ole Frithjof, Wilson Bruce M
Law clerk at the Constitutional Chamber of the Supreme Court of Costa Rica, San José, Costa Rica.
Professor at the University of Bergen, Norway.
Health Hum Rights. 2018 Jun;20(1):79-91.
In response to the incremental creation of an expansive constitutional right to health in Costa Rica, the country's rights-friendly constitutional chamber of the Supreme Court (known as the Sala IV) unleashed a flood of litigation for medications, treatments, and other health care issues. This development was met by widespread criticism from within the health sector, which complained that the court's jurisprudence routinely elevated the right to health above financial considerations, thus posing a threat to the financial well-being of the state-run health care system. Further, a 2014 study by Ole Frithjof Norheim and Bruce Wilson examining successful health rights litigation revealed that more than 70% of favorable rulings were for low-priority medications, suggesting a lack of fairness in access to medications in Costa Rica. To address some of these criticisms, the Sala IV initiated a partnership in 2014 with the Cochrane Collaboration to incorporate medical expert evaluations into its decision-making process for claims seeking access to medications. This article examines the court's reformed decision-making process to determine whether the increased reliance on medical expertise has changed health rights jurisprudence. We reviewed all medication claims from 2016 and classified the successful cases into four groups using standard priority-setting criteria. We then compared these results with rulings issued in 2008, prior to the court's reform (and the year analyzed in Norheim and Wilson's study). Our analysis reveals that under the court's new rules, the probability of winning a medication lawsuit has increased significantly; moreover, the percentage of rulings granting experimental medications has declined while the percentage granting high-priority medications has increased. Based on these results, in comparison to the court's pre-reform jurisprudence, we can tentatively conclude that the new process has led to some minor gains in fairness.
针对哥斯达黎加逐步确立的广泛的健康宪法权利,该国最高法院倾向于维护权利的宪法分庭(即第四庭)引发了大量关于药物、治疗及其他医疗保健问题的诉讼。这一发展遭到了医疗部门内部的广泛批评,该部门抱怨称,法院的判例法经常将健康权置于财务考量之上,从而对国营医疗保健系统的财务状况构成威胁。此外,奥勒·弗里特约夫·诺海姆和布鲁斯·威尔逊在2014年进行的一项关于成功的健康权诉讼的研究表明,超过70%的有利裁决涉及低优先级药物,这表明哥斯达黎加在药物获取方面缺乏公平性。为回应其中一些批评,第四庭于2014年与考科蓝协作网建立了合作伙伴关系,将医学专家评估纳入其关于获取药物索赔的决策过程。本文考察了该法院改革后的决策过程,以确定对医学专业知识的更多依赖是否改变了健康权判例法。我们审查了2016年所有的药物索赔,并使用标准的优先级设定标准将成功案例分为四类。然后,我们将这些结果与法院改革前(即诺海姆和威尔逊研究中所分析的年份)2008年发布的裁决进行了比较。我们的分析表明,根据法院的新规则,赢得药物诉讼的概率显著增加;此外,批准使用实验性药物的裁决比例下降,而批准使用高优先级药物的裁决比例上升。基于这些结果,与法院改革前的判例法相比,我们可以初步得出结论,新程序在公平性方面取得了一些小的进步。